US Patent 9,358,204: Viloxazine Extended-Release Formulation Claims and Patent Landscape

US Patent 9,358,204 is a formulation patent covering immediate-release and extended-release viloxazine multiparticulate dosage forms. Its independent claim requires a combined IR/XR formulation, an XR coating system with a defined release-control-agent-to-pore-former ratio, a viloxazine loading range, and a sustained-release performance requirement. The patent is materially narrower than a broad claim to viloxazine or to any once-daily viloxazine product.

The patent was issued July 5, 2016, and is assigned to Supernus Pharmaceuticals, Inc. It is associated with the Qelbree viloxazine extended-release franchise. Based on the standard US patent-term framework and the relevant filing history, the expected expiration date is March 6, 2032, subject to any patent-term adjustment, patent-term extension, terminal disclaimer, or other USPTO record affecting the term.[1]

What does US Patent 9,358,204 protect?

The patent protects a formulation that combines two populations of viloxazine-containing particles:

An immediate-release component.
An extended-release component.

The XR component must use a layered particle architecture:

An inert core.
A first layer containing viloxazine.
A second layer containing a release-rate-controlling compound and a pore former.

The claim also requires that at least 80% of the viloxazine be released over at least two hours in vitro. The patent therefore covers a specific drug-delivery architecture rather than the active ingredient itself.

Core claim limitations

Claim element	Scope required by claim 1
Active ingredient	Viloxazine or a viloxazine salt
IR component	Inert core with a viloxazine-containing surrounding layer
XR component	Inert core, viloxazine layer, and outer release-control layer
Release-control layer	Release-rate-controlling compound plus pore former
Pore-former ratio	Release-control compound:pore former of 19:1 to 8.5:1.5
Release-control compound	5% to 65% of the XR component
Total viloxazine loading	25% to 75% of the total formulation
Release profile	Immediate and continuous release after administration
In-vitro release	At least 80% released over at least two hours
Dosage form	Broadly includes capsules, tablets, beads, granules, powders, caplets and sprinkles through claim 12

The claim is composition-focused. It does not require a particular indication, such as attention-deficit/hyperactivity disorder, and it does not require a particular brand, capsule size, manufacturing process, or commercial dose.

How does claim 1 define the protected formulation?

Claim 1 uses multiple cumulative limitations. A competing product must satisfy each limitation literally or under an applicable doctrine-of-equivalents analysis for a direct infringement case.

Immediate-release component

The IR component is not merely viloxazine powder. It must include an inert core and a viloxazine-containing layer surrounding that core. This language points to coated beads, pellets, or similar multiparticulates.

A formulation using uncoated viloxazine crystals or a tablet matrix for the IR fraction may fall outside the literal scope of this limitation, depending on its structure. The claim does not specify the size, shape, composition, or material of the inert core.

Extended-release component

The XR component requires a three-level structure:

An inert core.
A viloxazine-containing first layer.
An outer layer containing the release-control compound and pore former.

This structure distinguishes the patent from:

A simple hydrophilic matrix tablet.
An uncoated extended-release pellet.
A tablet containing an IR fraction and an unrelated XR matrix.
A dosage form in which the drug is dispersed throughout the rate-controlling polymer layer rather than placed in a separate inner drug layer.

Claim 5 narrows the XR component to a plurality of particles. Claim 1 itself is broader in format, but the physical architecture still strongly implies coated multiparticulates.

Release-control compound

The claim includes a broad Markush list. The principal categories are:

Ethylcellulose.
Cellulose acetate.
Cellulose acetate butyrate.
Waxes.
Hydrogenated vegetable oils.
Glyceryl behenate.
Glyceryl palmitostearate.
PEG glyceryl esters.
Polyvinyl acetate.
Cellulose acetate propionate.
Acrylic and methacrylic copolymers, including Eudragit-type materials.
Combinations of listed materials.

Claim 3 narrows the list to ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, cellulose acetate propionate, and combinations.

Pore former

The pore former is limited to:

Povidone.
Hypromellose.
Hydroxyethyl cellulose.
Hydroxypropyl cellulose.
Organic acids.

A product using a pore former outside this list may avoid literal infringement of claim 1 unless the selected material is treated as an equivalent. The claim does not set a separate absolute concentration range for the pore former. Instead, it is constrained through the required ratio to the release-control compound.

What is the importance of the 19:1 to 8.5:1.5 ratio?

The ratio is one of the strongest narrowing limitations in claim 1.

The stated ratio translates to approximately:

Release-control compound:pore former of 19:1 at the high end.
Release-control compound:pore former of 8.5:1.5, or approximately 5.67:1, at the low end.

A formulation with a 10:1 ratio would fall within the claimed range. A formulation with a 5:1 ratio would be outside the literal numerical range, subject to claim-construction and equivalents arguments.

The ratio must be calculated using the relevant components in the second XR layer. A generic polymer-to-excipient ratio calculated across the entire dosage form may not answer the infringement question. The product’s manufacturing records, coating composition, and analytical composition would be important in determining whether the ratio is met.

What dependent claims add to US 9,358,204?

Claim	Additional limitation
2	Hydrophilic compound selected from a specified polymer and natural-polymer list
3	Narrower release-control-compound list
4	Release-control compound at 5% to 18% of the XR component
5	XR component is a plurality of particles
6	Once-daily administration
7	Twice-daily administration
8	10 mg to 800 mg viloxazine
9	Viloxazine hydrochloride
10	Cmax between 50% and 125% of IR viloxazine administered TID or BID
11	AUC over a 24-hour interval between 80% and 125% of IR viloxazine administered TID or BID
12	Specified dosage forms, including capsules, tablets, beads, granules and sprinkles
13	At least two XR components, each with its own release rate

Claims 10 and 11 add pharmacokinetic limitations. These claims may be difficult to assess from the product label alone because the relevant comparison is against IR viloxazine administered three times daily or twice daily. A challenger would likely need comparative pharmacokinetic data, not merely dissolution results.

What patents protect Qelbree and other viloxazine products?

The relevant US patent estate includes formulation patents associated with Supernus's extended-release viloxazine products. Public FDA and patent records should be reviewed together because the Orange Book identifies patents listed by the NDA holder, while USPTO records show the full patent family and prosecution history.[1][2]

Patent	General subject matter	Expected term position
US 9,358,204	IR/XR viloxazine formulation with coated particles and controlled release	Expected expiration around March 6, 2032
US 10,292,938	Additional viloxazine formulation or release technology in the same commercial estate	Generally aligned with the early-2030s estate
US 10,292,939	Related viloxazine formulation claims	Generally aligned with the early-2030s estate
Later continuation or related patents	Potentially narrower formulation, pharmacokinetic, or product claims	Expiration depends on each family and terminal-disclaimer history

The precise commercial barrier depends on which patents are listed for the applicable Qelbree NDA, whether the patents remain in force, and whether any listed patent has a terminal disclaimer or patent-term adjustment. A patent-family review should distinguish issued patents, abandoned applications, continuations, and patents that are merely related but not Orange Book listed.

What is the Orange Book status of US 9,358,204?

US 9,358,204 is relevant to the Qelbree extended-release viloxazine product and should be evaluated as an Orange Book formulation patent if listed against the applicable NDA.[2] Orange Book listing creates a regulatory notice and certification framework for ANDA applicants. It does not independently establish infringement or validity.

For an ANDA applicant, the possible certifications generally include:

Paragraph I: No patent information has been submitted.
Paragraph II: The listed patent has expired.
Paragraph III: The applicant will not market until patent expiration.
Paragraph IV: The listed patent is invalid, unenforceable, or will not be infringed.
Section viii statement: The applicant is carving out a patented method of use, when legally available.

Because US 9,358,204 is primarily a formulation patent, a Section viii carve-out is unlikely to eliminate all exposure if the generic product itself practices the claimed formulation. A Paragraph IV certification would be the more direct challenge route for a product using the claimed IR/XR architecture.

When does viloxazine lose regulatory exclusivity?

Qelbree was approved by the FDA on April 26, 2021, for ADHD in pediatric patients ages 6 to 17. The FDA later expanded the indication to adults.[3][4]

The relevant regulatory periods are distinct from patent expiration:

Protection type	Approximate timing
Original FDA approval	April 26, 2021
Five-year NCE period, if applicable to the NDA	Approximately April 26, 2026
Pediatric extension, if granted and applicable	Approximately October 26, 2026
Expected expiry of US 9,358,204	Approximately March 6, 2032
Earliest routine generic launch absent challenge or settlement	Generally after applicable patent and regulatory barriers

The FDA regulatory exclusivity period does not replace the patent estate. After regulatory exclusivity expires, an ANDA applicant may still face listed patents through the early 2030s.

Which companies are challenging Qelbree patents?

The key challenge mechanism is an ANDA Paragraph IV certification. A challenger must identify the listed patents it believes are invalid, unenforceable, or not infringed. The NDA holder may then bring a patent-infringement action within 45 days, triggering an FDA approval stay of up to 30 months under the Hatch-Waxman framework.[5]

The supplied claim set does not identify an ANDA filer, Paragraph IV notice, district-court docket, settlement, or authorized generic agreement. A definitive statement identifying current challengers or litigation outcomes cannot be made from the claim text alone.

For diligence purposes, the relevant search set includes:

Supernus Pharmaceuticals as NDA holder and patent owner.
Qelbree ANDA applicants.
Paragraph IV notices directed to US 9,358,204.
District Court for the District of Delaware filings.
New Jersey federal-court filings.
PTAB inter partes review petitions.
FDA Paragraph IV litigation and tentative-approval records.

How strong is the patent estate for US 9,358,204?

The patent has meaningful commercial value but a constrained infringement perimeter.

Strengths

It covers a commercially relevant IR/XR delivery design.
It claims both composition structure and performance.
The Markush list covers several conventional release-control materials.
Claim 4 provides a narrower 5% to 18% polymer-content fallback.
Claims 10 and 11 protect pharmacokinetic equivalence characteristics.
The claim reaches once-daily and twice-daily formulations.
Claim 13 can cover products using multiple XR populations with different release rates.

Vulnerabilities

The claim contains many cumulative structural limitations.
The specific pore-former list limits design freedom for the patent owner.
The numerical ratio creates a potential design-around route.
The 80%-over-two-hours release limitation may raise testing-protocol disputes.
“Immediate” and “continuously” may require claim construction.
The pharmacokinetic claims depend on a defined comparator and study design.
Conventional excipient combinations may create obviousness arguments if supported by prior art.
A product using a matrix system rather than coated inert cores may avoid literal infringement.

The strongest claims for enforcement are likely claims 1, 3, 4, 5, 8, 9 and 12 when a competing product uses viloxazine hydrochloride in coated multiparticulates with ethylcellulose or a similar membrane and a listed pore former. Claims 10 and 11 may provide valuable protection if the product’s pharmacokinetic profile is close to Qelbree but are more dependent on comparative evidence.

What generic launch risks exist?

Scenario 1: No Paragraph IV challenge

A generic applicant may be unable to obtain final approval until the relevant listed patents expire or are otherwise removed. The practical launch date would be in the early 2030s unless a patent is invalidated or a settlement permits an earlier entry.

Scenario 2: Paragraph IV challenge with litigation

The ANDA applicant could seek approval before patent expiration. Litigation could delay approval for up to the statutory stay period, while the court evaluates validity, enforceability, and infringement.

Scenario 3: Non-infringing formulation

A generic could attempt to avoid claim 1 by using:

A matrix-based XR system.
A different core architecture.
A pore former outside the claimed list.
A release-control-to-pore-former ratio outside the claimed range.
A formulation without a separately layered IR component.
A release profile that does not meet the claimed in-vitro limitation.

Such changes may create development, bioequivalence, manufacturing, or regulatory complications.

Scenario 4: Authorized or settlement-based entry

Supernus could resolve litigation through a settlement that sets an agreed launch date, license terms, supply arrangement, or authorized-generic structure. The commercial effect would depend on the number of licensees and whether the settlement preserves exclusivity against other applicants.

Does biosimilar risk apply to viloxazine?

No. Viloxazine is a small-molecule active pharmaceutical ingredient. The relevant competitive pathway is an ANDA for a generic drug, not a 351(k) biosimilar application. The primary regulatory issues are pharmaceutical equivalence, bioequivalence, patent certification, labeling, and formulation similarity.[5]

What manufacturing and IP barriers matter?

The formulation architecture creates several manufacturing barriers:

Consistent coating of the inert cores.
Uniform drug-layer deposition.
Control of the outer membrane thickness.
Accurate polymer-to-pore-former ratios.
Prevention of premature release from the IR fraction.
Reproducible dissolution across the full dose range.
Stability of viloxazine hydrochloride in the multiparticulate system.
Encapsulation or compression without damaging the coated particles.

A generic developer can avoid the patent through a different formulation, but that alternative must still meet FDA bioequivalence requirements. The patent therefore has greater practical value when its claimed architecture is closely tied to the approved product's dissolution and pharmacokinetic profile.

What is the geographic coverage of US 9,358,204?

US 9,358,204 provides protection only in the United States. Corresponding international or foreign-family patents must be assessed separately. A global freedom-to-operate review should examine:

PCT publications.
European Patent Office family members.
Canadian patents.
Japanese and South Korean family members.
Australian patents.
Patent grants in major manufacturing jurisdictions.
National-phase abandonment and expiration records.

A US patent does not block manufacture, sale, or use outside the United States unless a corresponding foreign patent is in force.

Key Takeaways

US 9,358,204 is a formulation patent, not a composition-of-matter patent on viloxazine.
Claim 1 requires a combined IR/XR formulation with layered inert-core particles.
The XR outer layer must contain a listed release-control compound and pore former within a defined ratio.
The total formulation must contain 25% to 75% viloxazine and release at least 80% over at least two hours in vitro.
Claims 10 and 11 add pharmacokinetic protection against IR-comparable once-daily or modified-release products.
The expected patent expiration is around March 6, 2032, subject to the official USPTO term calculation.
Generic competition would normally proceed through an ANDA and potentially a Paragraph IV certification.
Viloxazine has generic, not biosimilar, competitive risk.
The principal design-around opportunities involve matrix systems, different particle architectures, unlisted pore formers, and ratios outside the claimed range.
The commercial strength of the patent depends on the complete Orange Book estate, continuation patents, litigation history, and any settlement or license agreements.

Frequently Asked Questions

What active ingredient does US 9,358,204 cover?

It covers viloxazine and viloxazine salts, with claim 9 specifically identifying viloxazine hydrochloride.

Does US 9,358,204 cover every once-daily viloxazine product?

No. The product must satisfy the structural, compositional, ratio, and release limitations of the claims. Once-daily use alone is insufficient.

Can a generic avoid US 9,358,204 by changing the capsule strength?

Not necessarily. Claim 8 covers a broad range of 10 mg to 800 mg of viloxazine. A strength change alone may not avoid infringement.

Does a formulation need to use ethylcellulose to infringe?

No. Claim 1 includes several alternative release-control compounds. Ethylcellulose is only one listed option.

Is the two-hour release requirement a minimum duration for the product?

The claim requires at least 80% release over a period of at least two hours in vitro. The precise meaning depends on the applicable dissolution method, claim construction, and testing conditions.

Sources

United States Patent and Trademark Office. (2016). US Patent No. 9,358,204, modified release formulations of viloxazine.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2021). Qelbree (viloxazine extended-release capsules) prescribing information. Supernus Pharmaceuticals, Inc.
U.S. Food and Drug Administration. (2022). FDA approves expanded indication for Qelbree for adults with ADHD.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 355, 355(j); 21 C.F.R. §§ 314.94, 314.107.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-001	Apr 2, 2021		RX	Yes	No	9,358,204	⤷ Start Trial	Y				⤷ Start Trial
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-002	Apr 2, 2021		RX	Yes	No	9,358,204	⤷ Start Trial	Y				⤷ Start Trial
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-003	Apr 2, 2021		RX	Yes	Yes	9,358,204	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013217013	⤷ Start Trial
Australia	2017206245	⤷ Start Trial
Australia	2019216707	⤷ Start Trial
Australia	2020233746	⤷ Start Trial
Canada	2864088	⤷ Start Trial
European Patent Office	2812074	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,358,204

Which drugs does patent 9,358,204 protect, and when does it expire?

Summary for Patent: 9,358,204